GIL: a blood group system review by Rumsey, Dawn M. & Mallory, Delores A.
IMMUNOHEMATOLOGY, Volume 29, Number 4, 2013 141
GIL: a blood group system review
D.M. Rumsey and D.A. Mallory
The GIL blood group system was added to the list of systems already 
recognized by the International Society for Blood Transfusion in 
2002. It was designated as system 29 after the antigen was located 
on the aquaglyceroporin 3 (AQP3) protein and the gene encoding 
the protein was identified in 2002. There is only one antigen 
in the system, GIL, and the antigen, as well as the system, was 
named after the antigen-negative proband identified in the United 
States who had made anti-GIL. It was later shown to be the same 
as an unidentified high-incidence antigen lacking from the red 
blood cells of a French woman. Coincidentally all the antibodies 
found have been produced as a result of pregnancy. While there 
has not been a direct link to a disease, the absence of the AQP3 
protein may result in a worse than expected rate of survival of 
patients with bladder cancer as compared with patients with the 
same disease who express the protein. Future work may center 
on using GIL as a marker for AQP3 and involving it in targeted 
cancer therapies. Immunohematology 2013;29:141–144
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History
The GIL blood group was designated as system 29 
by the International Society for Blood Transfusion (ISBT) 
Committee on Terminology for Red Cell Surface Antigens 
(current name: Working Party for Red Cell Immunogenetics 
and Blood Group Terminology) after its meeting in Vancouver, 
Canada, in August 2002 (Table1).1 GIL takes its name from 
the first proband, the American reported by Frederick et al. 
in 1981.2 Thanks to an exchange of cells and sera between 
Daniels, working in England, and the French group, a sample 
of cells and sera from a French woman (Boi) collected in 1979 
was found to be compatible with the cells and sera from the 
American proband, Gill. The French woman, born in 1925, 
had 10 pregnancies before her antibody was detected. Gill 
was born in 1956, and her antibody was detected after her 
first child was delivered in 1979. GIL had not met the ISBT 
requirements to be recognized as a system as the antigen, or 
the antigen-negative phenotype, had not been shown to be 
inherited, until the antigen was located on aquaglyceroporin 3 
(AQP3) by Roudier et al. in 2002.3
Serology
GIL
GIL is the only antigen in the GIL system and has an 
incidence of almost 100 percent in French, German, and 
American populations.4 Daniels et al. used examples of anti-
GIL to determine the effect of enzyme and chemical treatment 
on the antigen. The expression of GIL is not affected by 
treatment with dithiothreitol. However, GIL was enhanced by 
treatment with papain, ficin, α-chymotrypsin, and trypsin. 
Expression of the antigen appears slightly weaker on cord cells 
when compared with reactivity with red blood cells (RBCs) 
from adults.5
GIL has not been found on platelets, but it is expressed 
on tissue from the kidney medulla and cortex, basolateral 
membrane of collecting duct cells, small intestine, stomach, 
colon, spleen, skin, airways, and eye.4
Anti-GIL
Anti-GIL did not react by the direct agglutination method 
but did react by the indirect antiglobulin test. The serum from 
the French proband (Boi) was obtained after a hemolytic 
transfusion reaction. Using a two-stage complement method, 
this antibody was found to bind complement, although the 
antibody from the American proband (Gill) did not.5 Anti-GIL 
was not inhibited by plasma, saliva, hydatid cyst fluid, Lewis 
substance, milk, urine, or pigeon protein.2,5
Three samples of the first five GIL antibodies were 
available in sufficient quantity for complement fixation testing. 
Only the antibody from the French proband fixed complement 
when tested using a two-stage method. As this sample was 
then exhausted, immunoglobulin subclassing and monocyte 
monolayer assays (MMA) were performed on only two of 
the anti-GIL samples (Gill and Hun). The antibody from the 
American proband tested as IgG1. The antibody from the third 
sample (Hun) was found to be IgG1 plus IgG2. All testing was 
carried out by methods previously described.6,7 Both samples 
revie w
Table 1. The GIL blood group system as recognized by ISBT
ISBT System Antigen Gene
Name Gill GIL AQP3 (GIL if inferred by 
hemagglutination)
Symbol GIL GIL1
Number 029 029001 (or 29.1)
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of anti-GIL appeared clinically significant with MMA results 
of 22 percent and 23 percent with one sample and 32 percent 
and 27 percent with the other. The MMA normal range is 0 to 
3 percent.5
Before the genetic basis of GIL was elucidated, 
immunoblotting was carried out using an eluate prepared with 
the Gill antibody. No bands were detected under reducing or 
nonreducing conditions.5 Because neither the genetic basis nor 
the pattern of inheritance could be provided, initially no ISBT 
number was assigned.
Genetics
The AQP3 gene (NCBI accession # NM_004925) is 
composed of six exons distributed over more than 7 kb of 
DNA located on human chromosome 9p13 (Fig. 1A).8 The 
gene encodes a multipass transmembrane protein of 292 
amino acids that spans the cell membrane six times with 
amino and carboxyl terminals located in the cytoplasm (Fig. 
1B).9 The protein has an N-glycosylation site at Asn141 located 
in the third extracellular loop and exists as dimers, trimers, 
and tetramers.9 Roudier et al.3 used transcript analysis to 
investigate AQP3 expression in the GIL– probands. They 
demonstrated an abnormal transcript, missing exon 5, that 
they termed AQP3 (delta5). DNA sequence analysis showed 
a single-nucleotide polymorphism (SNP) in a splice site 
(IVS5+1g>a) that would result in exon skipping. The aberrant 
mRNA is predicted to encode a truncated protein lacking 
amino acids 165 to 237 and thus have a unique C-terminus as 
a result of a frameshift.3
The IVS5+1g>a polymorphism destroys the recognition 
site for the restriction enzyme PmlI, such that a polymerase 
chain reaction restriction fragment length polymorphism 
assay can be used to screen DNA for the presence of the 
variant. A sibling and the ten children of the French proband 
were found to be heterozygous for the IVS5+1g>a SNP.
No AQP3 was detected in RBC membranes from the 
probands, supporting the characterization of this allele as 
a null allele. Sera from the American and French probands 
reacted specifically with COS-7 cells transiently expressing 
full-length AQP3 cDNA, demonstrating that the AQP3 gene 
encodes the GIL antigen. The normal AQP3 gene that encodes 
the GIL antigen has been assigned GIL*01 as the allele name 
by the ISBT Working Party for Red Cell Immunogenetics and 
Blood Group Terminology, the IVS5+1g>a allele is assigned 
GIL*01N.01.4
Biochemistry
Aquaporins are integral membrane proteins that facilitate 
the transport of water and other solutes across the cell 
membrane. AQP3 is one of two AQP proteins that have been 
found on human RBCs. Whereas AQP1 is responsible for the 
high permeability of the RBC membrane to water, AQP3 allows 
permeability to glycerol and, to a lesser extent, urea. AQP1 
has been shown to express Colton blood group antigens.10,11 
Roudier et al.3 hypothesized that AQP3 also could be encoded 
by a blood group gene, and their work elucidated the molecular 
basis of GIL.
By collecting RBC samples from 24 individuals who lacked 
a high-incidence antigen and had made the corresponding 
antibody, and testing them by immunoblotting using anti-
rAQP3, only the American and French GIL− probands were 
nonreactive. RBC membranes from both probands lacked both 
the glycosylated and deglycosylated forms of AQP3 protein 
that were visualized on the control cell membranes.3
The absence of the AQP3 protein on the two samples of 
GIL– RBCs was supported by the lack of glycerol permeability 
shown by both samples. This was determined by stopped-flow 
analysis. Interestingly, the controls (GIL+ RBCs) could have 
their glycerol transport inhibited to the same level shown by the 
probands lacking AQP3 by the addition of CuCl2. This implies 
that there is no alternative channel for glycerol permeability in 
the RBC membrane.3
Fig. 1a Schematic of gene with six exons (boxes) spanning 6 
kilobases on chromosome 9p13. The gray portion of exons 1 and 6 
represents the 5′ and 3′ untranslated regions, respectively.
Fig. 1b Schematic of protien in RBC lipid bilayer. Protien is 292 
amino acids, with both N and C terminus in the cytoplasm with one 
N-glycosylation site (ball and stick) in third extracellular domain.
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Incidence and Relationship to Disease
The incidence of GIL is almost 100 percent in the 
German, French, and American populations. The screening 
of 26,391 American donors included 23,499 white donors, 
2841 black donors, and 101 Asian donors. All of these were 
GIL+.5 Combined with the understanding that AQP3 is a very 
common protein on RBCs, could there be polymorphisms 
within a specific race that would be associated with a specific 
disease?
Bahamontes-Rosa et al.12 identified five SNPs in the AQP3 
gene in a group of African children affected by malaria. The 
three SNPs located in the coding regions were synonymous, 
having no impact on the amino acid composition of the protein. 
The two SNPs located in the promoter region were examined 
for their impact on AQP3 expression; none was found.12
Testing of mRNA content in patients with severe malarial 
anemia or uncomplicated malaria did show a significantly 
lower amount of AQP3 mRNA in the anemic patients when 
compared with either the uncomplicated malaria group or 
the control group. The difference in AQP3 expression in the 
severely anemic group could be accounted for by the use of 
quinine in their treatment and the abnormal erythropoiesis 
with inadequate reticulocyte response. Therefore, unlike the 
mouse model in which mice deficient for AQP9 are partially 
protected from infection with Plasmodium berghei, AQP3 
deficiency in the black population is not likely to confer even 
partial protection from malaria.12,13
More recently, AQP3 has been investigated for its role 
in cancer. Loss of AQP3 expression was associated with a 
worse progression-free survival in urothelial bladder cancer.14 
Evidence suggests that AQP3 participates in the cytotoxic 
response to nucleoside analogs, such as gemcitabine, used 
as chemotherapeutic agents, as well as arsenite.15,16 AQP3 
expression levels may be of diagnostic utility in some cancers 
shown to be linked to colorectal, gastric carcinoma, and breast 
cancer cell migration.17–19 Demonstration of the AQP3-specific 
inhibitor CuSO4 in cell culture models suggests that AQP3 
may be a target of cancer therapies.19
Summary
From the original antibody found compatible with 
the second proband in 1979 to acceptance by the ISBT as a 
unique blood group system in 2002, it took 23 years for the 
GIL system to be given its own place among the other unique 
blood group systems. The assignment of the GIL antigen to 
AQP3 was based on a gene-centric approach in which Roudier 
et al.3 sequenced the coding regions of the AQP3 gene in 
probands lacking the GIL antigen, hypothesizing that AQP3 
could harbor a blood group antigen as was the case with AQP1 
and the Colton blood group system. The GIL system has one 
antigen. The null phenotype is rare, being found in French and 
American (one of German ancestry) probands. The exchange 
of antisera and cells among reference laboratories was critical 
to the completion of the work to establish GIL as a blood 
group system. Collaboration among reference laboratories 
is invaluable and must continue so that we may continue to 
explore new relationships between serologic and molecular test 
findings. Molecular testing has opened the door to confirming 
suspicions long held but never proven, and it is likely that 
the cloning of genes will elucidate so much more information 
about the function, structure, and relationship to disease of all 
blood group systems.
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